https://www.selleckchem.com/pr....oducts/Sunitinib-Mal
According to current FDA guidelines for example for first line therapy of urothelial cancer with pembrolizumab (CPS ≥ 1, a subset of SCC patients up to 20% would be eligible. Finally, our UC/SCC index patient revealed excellent therapy response regarding his lung metastasis. CONCLUSIONS Our data reveal a PD-L1 expression in squamous differentiated carcinomas comparable with current data shown for urothelial tumours. In accordance with the encouraging clinical data of the index patient we suggest ICI treatment also fo
Like
Comment
Share
